Kerry Fenwick

8.9k total citations · 2 hit papers
60 papers, 4.9k citations indexed

About

Kerry Fenwick is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Kerry Fenwick has authored 60 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 25 papers in Cancer Research and 19 papers in Oncology. Recurrent topics in Kerry Fenwick's work include Cancer Genomics and Diagnostics (18 papers), Genomic variations and chromosomal abnormalities (11 papers) and Genomics and Chromatin Dynamics (10 papers). Kerry Fenwick is often cited by papers focused on Cancer Genomics and Diagnostics (18 papers), Genomic variations and chromosomal abnormalities (11 papers) and Genomics and Chromatin Dynamics (10 papers). Kerry Fenwick collaborates with scholars based in United Kingdom, United States and Canada. Kerry Fenwick's co-authors include Alan Ashworth, Alan Mackay, Iwanka Kozarewa, Christopher J. Lord, Jorge S. Reis‐Filho, Nicholas C. Turner, Alan Ashworth, Ioannis Assiotis, Rachael Natrajan and Marjan Iravani and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Kerry Fenwick

59 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

2015 416 citations Sarah Hrebien, Isaac García-Murillas et al. profile →
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

2018 401 citations Ben O’Leary, Rosalind Cutts et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kerry Fenwick United Kingdom	38	2.8k	2.2k	1.9k	1.1k	850	60	4.9k
Thomas Januario United States	12	3.4k 1.2×	2.1k 1.0×	894 0.5×	1.3k 1.2×	438 0.5×	19	4.8k
Caterina Marchiò Italy	42	2.2k 0.8×	2.9k 1.3×	2.4k 1.3×	984 0.9×	486 0.6×	163	5.8k
A. Hunter Shain United States	23	2.8k 1.0×	2.1k 0.9×	1.2k 0.7×	571 0.5×	426 0.5×	36	4.6k
Federico A. Monzon United States	34	2.2k 0.8×	1.6k 0.7×	1.5k 0.8×	1.4k 1.3×	388 0.5×	114	4.4k
Mingming Jia China	12	3.7k 1.3×	1.5k 0.7×	2.1k 1.1×	896 0.8×	840 1.0×	19	5.6k
Rachael Natrajan United Kingdom	48	4.7k 1.7×	3.7k 1.7×	2.9k 1.6×	1.0k 1.0×	1.1k 1.3×	112	7.9k
Kay Savage United Kingdom	42	2.8k 1.0×	2.6k 1.2×	2.1k 1.1×	647 0.6×	630 0.7×	66	5.7k
Ritva Karhu Finland	37	2.6k 0.9×	1.2k 0.6×	1.7k 0.9×	759 0.7×	1.8k 2.1×	72	4.7k
Michel Longy France	35	2.4k 0.9×	1.3k 0.6×	864 0.5×	412 0.4×	940 1.1×	93	4.0k
Fernanda Milanezi Portugal	36	1.7k 0.6×	1.9k 0.9×	1.2k 0.7×	686 0.6×	332 0.4×	75	4.0k

Countries citing papers authored by Kerry Fenwick

Since Specialization

Citations

This map shows the geographic impact of Kerry Fenwick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry Fenwick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry Fenwick more than expected).

Fields of papers citing papers by Kerry Fenwick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry Fenwick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry Fenwick. The network helps show where Kerry Fenwick may publish in the future.

Co-authorship network of co-authors of Kerry Fenwick

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry Fenwick. A scholar is included among the top collaborators of Kerry Fenwick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry Fenwick. Kerry Fenwick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davidson, Edgar, Tara L. Jones, Wasim Baqir, & Kerry Fenwick. (2023). Does the implementation of self-administration policies for insulin improve patient safety in the hospital inpatient setting? A scoping review. International Journal of Pharmacy Practice. 31(Supplement_2). ii16–ii16.

Loga, Katharina von, Andrew Woolston, Marco Punta, et al.. (2020). Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications. 11(1). 139–139. 43 indexed citations

Knebel, Franciele Hinterholz, Louise J. Barber, Alice Newey, et al.. (2020). Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. Cancers. 12(12). 3736–3736. 4 indexed citations

O’Leary, Ben, Rosalind Cutts, Yuan Liu, et al.. (2018). The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery. 8(11). 1390–1403. 401 indexed citations breakdown →

Leavy, Olivia C., Nicola H. Dryden, Sarah Maguire, et al.. (2018). Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. Nature Communications. 9(1). 1028–1028. 72 indexed citations

Wilkins, Anna, Ritika Chauhan, Alistair G. Rust, et al.. (2018). FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. Breast Cancer Research and Treatment. 170(3). 573–581. 4 indexed citations

Pettitt, Stephen J., Dragomir B. Krastev, Helen N. Pemberton, et al.. (2017). Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. Scientific Data. 4(1). 170020–170020. 13 indexed citations

Francis, Jeffrey C., Lorenzo Melchor, James Campbell, et al.. (2015). Whole‐exome DNA sequence analysis of Brca2‐ and Trp53‐deficient mouse mammary gland tumours. The Journal of Pathology. 236(2). 186–200. 11 indexed citations

Pender, Alexandra, Isaac García-Murillas, Sareena Rana, et al.. (2015). Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE. 10(9). e0139074–e0139074. 48 indexed citations

10.

Murugaesu, Nirupa, Marjan Iravani, Antoinette van Weverwijk, et al.. (2014). An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor. Cancer Discovery. 4(3). 304–317. 75 indexed citations

11.

Bajrami, Ilirjana, Jessica Frankum, Asha Konde, et al.. (2013). Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity. Cancer Research. 74(1). 287–297. 279 indexed citations

12.

Furney, Simon J., Samra Turajlic, Kerry Fenwick, et al.. (2012). Genomic characterisation of acral melanoma cell lines. Pigment Cell & Melanoma Research. 25(4). 488–492. 27 indexed citations

13.

Barber, Louise J., Iwanka Kozarewa, Kerry Fenwick, et al.. (2011). Comprehensive Genomic Analysis of a BRCA2 Deficient Human Pancreatic Cancer. PLoS ONE. 6(7). e21639–e21639. 12 indexed citations

14.

Westbury, Charlotte, Jorge S. Reis‐Filho, Tim Dexter, et al.. (2009). Genome‐wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c‐Kit, CD117) and oestrogen receptor‐α (ERα) in response to therapeutic radiation. The Journal of Pathology. 219(1). 131–140. 32 indexed citations

15.

Marchiò, Caterina, Rachael Natrajan, David S.P. Tan, et al.. (2008). The genomic profile of HER2‐amplified breast cancers: the influence of ER status. The Journal of Pathology. 216(4). 399–407. 64 indexed citations

16.

Mackay, Alan, Ander Urruticoechea, J. Michael Dixon, et al.. (2007). Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Research. 9(3). R37–R37. 97 indexed citations

17.

Smalley, Matthew J., Marjan Iravani, Maria Leao, et al.. (2007). Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Research. 9(6). R85–R85. 25 indexed citations

18.

Reis‐Filho, Jorge S., Peter T. Simpson, Nicholas C. Turner, et al.. (2006). FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas. Clinical Cancer Research. 12(22). 6652–6662. 215 indexed citations

19.

Arriola, Edurne, Maryou B. Lambros, Chris Jones, et al.. (2006). Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Laboratory Investigation. 87(1). 75–83. 46 indexed citations

20.

Little, Suzanne E., Raisa Vuononvirta, Jorge S. Reis‐Filho, et al.. (2005). Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics. 87(2). 298–306. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact